Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(170 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(86 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(78 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(27 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1375 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ROS kinases-IN-1
CAS:<p>ROS kinases-IN-1 is a ROS tyrosine kinase inhibitor with IC50 value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity.</p>Fórmula:C20H16N4OPureza:97.36%Cor e Forma:SoildPeso molecular:328.37CH7233163
<p>CH7233163 is a useful organic compound for research related to life sciences and the catalog number is T35334.</p>Pureza:98%Cor e Forma:SolidUmikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Cor e Forma:Odour LiquidJBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Fórmula:C33H30F4N4O5SCor e Forma:SolidPeso molecular:670.67Dalmitamig
<p>Dalmitamig is a humanized IgG4κ antibody targeting EGFR/CD28, with HumanIgG4(S228P) kappa as its corresponding isotype control.</p>Cor e Forma:Odour LiquidSelf-assembling peptide pY1
<p>Self-assembling peptide pY1, which aggregates around cancer cells, specifically targets the EGFR receptor. When co-cultured with Ovalbumin (OVA), pY1 effectively inhibits the endocytosis of OVA.</p>Fórmula:C104H125N24O29PCor e Forma:SolidPeso molecular:2206.22Taletrectinib free base
CAS:<p>Taletrectinib (AB-106) is a potent, selective oral ROS1/NTRK inhibitor with low IC50s against ROS1 and NTRK1-3, including Crizotinib-resistant mutations.</p>Fórmula:C23H24FN5OPureza:99.98%Cor e Forma:SolidPeso molecular:405.47CRB-0089
<p>CRB-0089 is a human monoclonal antibody targeting NGF/bNGF. It is used in the study of analgesia.</p>Cor e Forma:Odour LiquidFicerafusp alfa
<p>Ficerafusp alfa is a chimeric antibody of the IgG1κ type that targets EGFR, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Cor e Forma:Odour LiquidAG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Cor e Forma:SolidPeso molecular:352.21EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PCor e Forma:SolidPeso molecular:805.72VEGFR-2-IN-33
<p>VEGFR-2-IN-33 (Compound 4d), a potent VEGFR inhibitor with an IC50 value of 61.04 nM, demonstrates significant inhibition of HepG2 cell proliferation, achieving</p>Fórmula:C20H14N6O2S2Pureza:98%Cor e Forma:SolidPeso molecular:434.49c-Met-IN-18
<p>C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.</p>Fórmula:C21H15FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:374.37FGFR1 inhibitor-8
<p>FGFR1 inhibitor-8 (Compound 9), an FGFR1 inhibitor with an IC50 of 0.5 nM, binds to the ATP-binding pocket of FGFR1 and exhibits anticancer activity [1].</p>Fórmula:C26H18ClNO5Pureza:98%Cor e Forma:SolidPeso molecular:459.88GW297361
CAS:<p>GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1</p>Fórmula:C16H12N4O3S2Pureza:97.02%Cor e Forma:SolidPeso molecular:372.42EGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Fórmula:C49H53ClFN5O5Cor e Forma:SolidPeso molecular:846.43UniPR1449
<p>UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].</p>Pureza:98%Cor e Forma:Odour SolidEGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Cor e Forma:SolidPeso molecular:429.24163Cofetuzumab
CAS:<p>Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.</p>Pureza:>95%Cor e Forma:LiquidEGFR-IN-129
<p>EGFR-IN-129 (Compound 10b) is an effective, selective EGFR inhibitor with an IC50 of 51.2 nM and demonstrates broad-spectrum antiproliferative activity against the NCI tumor panel.</p>Fórmula:C21H18N4O3SCor e Forma:SolidPeso molecular:406.46Nezutatug
CAS:<p>Nezutatug, an anti-HER3 antibody, serves as a research tool in cancer studies [1].</p>Pureza:98%Cor e Forma:LiquidAZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Fórmula:C23H15ClF2N6O2Cor e Forma:SolidPeso molecular:480.854ALKBH5-IN-5
CAS:<p>ALKBH5-IN-5 is a highly selective, potent and covalently binding ALKBH5 inhibitor that alters m6A levels on mRNA, induces apoptosis, antitumo.</p>Fórmula:C13H13NO3Pureza:99.54%Cor e Forma:SoildPeso molecular:231.25CT52923
CAS:<p>CT52923: selective oral PDGFR blocker, ATP-inhibitor, used in research for various diseases including cancer.</p>Fórmula:C23H25N5O4SPureza:99.926%Cor e Forma:SoildPeso molecular:467.54Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidLMTK3-IN-1
CAS:<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Fórmula:C18H11F3N4OPureza:99.89%Cor e Forma:SoildPeso molecular:356.3Adimanebart
CAS:<p>Amdokitug is a human-derived IgG1λ monoclonal antibody that acts as an inhibitor of MUSK.</p>Cor e Forma:LiquidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Cor e Forma:Odour SolidFLT3-ITD-IN-2
<p>FLT3-ITD-IN-2 (Compound A1) is an inhibitor of the FLT3-ITD kinase, exhibiting an IC50 of 2.12 nM. It effectively suppresses the proliferation of the FLT3-dependent human AML cell line MOLM-13, with an IC50 of 25.65 nM. FLT3-ITD-IN-2 demonstrates antitumor activity against acute myeloid leukemia.</p>Fórmula:C39H50N8O6Cor e Forma:SolidPeso molecular:726.86U3-1565
<p>U3-1565 (Anti-HB-EGF antibody) is an antibody targeting HB-EGF with potential anti-tumor activity, used in the study of advanced solid tumors.</p>Cor e Forma:LiquidPeso molecular:144.82 kDa (Predicted)VEGFR-2-IN-31
<p>VEGFR-2-IN-31 (compound 3i), a robust VEGFR-2 inhibitor (IC50=8.93 nM), serves as an anti-prostate cancer agent by arresting the cell cycle at the S-phase and</p>Fórmula:C15H10F2N4OPureza:98%Cor e Forma:SolidPeso molecular:300.26ALW-II-49-7
CAS:<p>ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.</p>Fórmula:C21H17F3N4O2Pureza:99.72%Cor e Forma:SoildPeso molecular:414.38AMG-820
<p>AMG-820 is a human antibody targeting CSF-1R, inhibiting the binding of ligands CSF1 and IL34, and preventing subsequent ligand-induced receptor activation. For AMG-820's isotype control, refer to [Human IgG2 kappa, Isotype Control].</p>Cor e Forma:Odour LiquidPyrithyldione
CAS:<p>Pyrithyldione is a sedative-hypnotic agent known to potentially induce agranulocytosis.</p>Fórmula:C9H13NO2Cor e Forma:SolidPeso molecular:167.21EGFR-IN-76
CAS:<p>EGFR-IN-76 is a potent EGFR inhibitor.</p>Fórmula:C30H30ClFN6O2Pureza:97.02% - 97.72%Cor e Forma:SolidPeso molecular:561.05VEGFR-2-IN-59
<p>VEGFR-2-IN-59 (Compound 3h) is an inhibitor of VEGFR2 with an IC50 of 3.73 µM. It exhibits cytotoxicity in cancer cell lines A549, HT-29, A375, MCF7, and NHDF, with IC50 values of 20.91, 19.70, 9.63, 17.43, and 20.71 μM, respectively. VEGFR-2-IN-59 also inhibits tubular structure formation and demonstrates anti-angiogenic properties.</p>Fórmula:C19H20N6O4Cor e Forma:SolidPeso molecular:396.4Befotertinib
CAS:<p>Befotertinib (D-0316) is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.</p>Fórmula:C29H32F3N7O2Pureza:99.83%Cor e Forma:SolidPeso molecular:567.61JAK1/2/3 Inhibitor 1
CAS:<p>JAK1/2/3 Inhibitor 1 is a potent protein kinase inhibitor.JAK1/2/3 Inhibitor 1 has antitumor activity that inhibits the growth of a variety of cancer cell lines</p>Fórmula:C6H2Cl2N2SPureza:99.32%Cor e Forma:SolidPeso molecular:205.06Varlitinib
CAS:<p>Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.</p>Fórmula:C22H19ClN6O2SPureza:99.7%Cor e Forma:SolidPeso molecular:466.94Valanafusp alfa
CAS:<p>Valanafusp alfa (AGT-181) is a fusion protein targeting HIR and IDUA for MPS I research.</p>Cor e Forma:LiquidEGFR-IN-138
<p>EGFR-IN-138 (compound 19) is a potent inhibitor of EGFR, with IC50 values of 37, 2.6, and 1.9 nM for the wild-type, L858R, and T790M EGFR, respectively.</p>Fórmula:C42H37N7O5Cor e Forma:SolidPeso molecular:719.793-Hydroxy Midostaurin
CAS:<p>3-Hydroxy Midostaurin (CGP 52421), a PKC412 metabolite, inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50 values of roughly 132 nM in</p>Fórmula:C35H30N4O5Pureza:98%Cor e Forma:SolidPeso molecular:586.648HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Fórmula:C26H23ClF2N8O3Cor e Forma:SolidPeso molecular:568.96HNMPA
CAS:<p>HNMPA blocks insulin receptor kinase, halting autophosphorylation; no impact on cAMP protein kinase or PKC.</p>Fórmula:C11H11O4PPureza:99.18%Cor e Forma:SolidPeso molecular:238.18VGB3
<p>VGB3 is a peptide antagonist of vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2, exhibiting anti-angiogenic and anti-tumor properties. It binds to VEGFR1 and VEGFR2, thereby inhibiting VEGF-driven endothelial cell proliferation, migration, and tube formation, as well as suppressing tumor growth and metastasis in a mouse 4T1 breast cancer model.</p>Fórmula:C67H101N19O21S2Cor e Forma:SolidPeso molecular:1572.76VEGFR2-IN-4
<p>VEGFR2-IN-4 (compound 25) is a potent, selective inhibitor of the VEGFR2 kinase, exhibiting a GI50 of 0.7 nM and demonstrating anti-angiogenic effects.</p>Fórmula:C23H20N4O3SPureza:98%Cor e Forma:SolidPeso molecular:432.49Compound TPX-0046
CAS:<p>Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.</p>Fórmula:C21H21FN6O3Pureza:99.94%Cor e Forma:SoildPeso molecular:424.43CREBtide
CAS:<p>CREBtide is a synthetic substrate for PKA (Km=3.9 µM), which is based on the phosphorylation sequence in d-CREB (cAMP response element binding protein).</p>Fórmula:C73H129N29O19Pureza:98%Cor e Forma:SolidPeso molecular:1716.99VEGFR-2-IN-32
<p>VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2, exhibiting an inhibitory concentration (IC 50) of 8.93 nM, and demonstrates cytotoxic activity towards PC-3</p>Fórmula:C15H12N4OPureza:98%Cor e Forma:SolidPeso molecular:264.28CSF1R-IN-17
<p>CSF1R-IN-17 (compound 9) is a potent, selective antagonist of CSF1R, exhibiting an inhibition concentration half-maximum (IC50) of 0.2 nM.</p>Fórmula:C20H25N5O2Pureza:98%Cor e Forma:SolidPeso molecular:367.44Tyrosine kinase-IN-7
CAS:<p>Tyrosine kinase-IN-7 is a potent inhibitor of the tyrosine kinase EGFR, inhibiting EGFR(WT) and EGFR(T790M) and showing anti-cancer and anti-tumor activity.</p>Fórmula:C16H15N3OSPureza:99.93%Cor e Forma:SolidPeso molecular:297.38BLU-945
CAS:<p>BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).Cost-effective and quality-assured.</p>Fórmula:C28H37FN6O3SPureza:99.11% - 99.16%Cor e Forma:SolidPeso molecular:556.7Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Cor e Forma:SolidPeso molecular:811.34Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Pureza:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:LiquidEGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Fórmula:C17H15N7O5SCor e Forma:SolidPeso molecular:429.41Oritinib
CAS:<p>Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (</p>Fórmula:C31H37N7O2Pureza:99.62%Cor e Forma:SoildPeso molecular:539.67PF-04217903 phenolsulfonate
CAS:<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Fórmula:C25H22N8O5SPureza:98%Cor e Forma:SolidPeso molecular:546.56Petosemtamab (FUT8-KO)
<p>Petosemtamab (FUT8-KO) is a variant of Petosemtamab with the fucosyltransferase 8 gene (FUT8) knocked out. Petosemtamab is a monoclonal antibody (mAb) targeting EGFR (with a Kd of 0.22 nM) and LGR5 (with a Kd of 0.86 nM). This antibody disrupts EGFR signaling and causes receptor degradation in LGR5+ cancer cells. It is applicable in research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).</p>Cor e Forma:Odour LiquidVEGFR-2-IN-35
<p>VEGFR-2-IN-35 (compound 7) is a potent inhibitor of VEGFR-2, exhibiting an IC50 of 37 nM.</p>Fórmula:C25H19N3O3Pureza:98%Cor e Forma:SolidPeso molecular:409.44PROTAC c-Met degrader-1
CAS:<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Fórmula:C45H41FN10O5Cor e Forma:SolidPeso molecular:820.87Gefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Fórmula:C22H24ClFN4O41·5HClCor e Forma:SolidPeso molecular:517.59TX2-120-1
CAS:<p>TX2-120-1 possesses the ability to bind with Her3, exhibiting an IC50 of 56 nM for Her3. It can be utilized in the synthesis of TX2-121-1.</p>Fórmula:C26H27N7O2Cor e Forma:SolidPeso molecular:469.54Amivantamab (FUT8-KO)
<p>Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.</p>Fórmula:C13H12O4Cor e Forma:LiquidPeso molecular:232.23Zenocutuzumab
CAS:<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Pureza:97%Cor e Forma:LiquidFRF-06-057
<p>FRF-06-057 is an allosteric ATP EGFR inhibitor targeting both wild-type and mutant EGFR, with IC50 values of 17 nM (LR/TM), 29 nM (LR/TM/CS), 220 nM (LR), and >1000 nM (WT).</p>Fórmula:C19H13N3O3SCor e Forma:SolidPeso molecular:363.394-Epidoxycycline
CAS:<p>4-Epidoxycycline is a hepatic metabolite of the antibiotic doxycycline and lacks antibiotic properties in mice. In both in vitro assays and in vivo mouse models, 4-Epidoxycycline regulates HER2 gene expression similarly to doxycycline and exhibits comparable efficacy in tumor tissues, achieving over 95% tumor regression rates.</p>Fórmula:C22H24N2O8Cor e Forma:SolidPeso molecular:444.44Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Cor e Forma:SolidPeso molecular:915.028SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Fórmula:C25H29F3N4O3Cor e Forma:SolidPeso molecular:490.52EGFR-IN-128
<p>EGFR-IN-128 (compound 28) is a potent and selective molecule targeting wild-type EGFREx20Ins, demonstrating therapeutic efficacy across various human xenograft models and capable of penetrating the blood-brain barrier in preclinical species.</p>Fórmula:C27H20N4OCor e Forma:SolidPeso molecular:416.47IMPDH2-IN-4
<p>IMPDH2-IN-4 (compound 2d) is a Mycophenolic acid analog and a selective IMPDH2 inhibitor with a Ki of 1.8 μM. It exhibits potent cytotoxic activity against osteosarcoma cancer cell lines. Additionally, IMPDH2-IN-4 demonstrates high affinity for VEGFR-2, CDK2, and IMPDH.</p>Fórmula:C35H34O6SiCor e Forma:SolidPeso molecular:578.73Atuzabrutinib
CAS:<p>Atuzabrutinib (SAR 444727) is a selective BTK inhibitor and can be used to study arthritis in rheumatoid rodents and pemphigus vulgaris.</p>Fórmula:C30H30FN7O2Pureza:97.27% - 99.38%Cor e Forma:SolidPeso molecular:539.6LCB 03-0110 dihydrochloride
CAS:<p>LCB 03-0110 Dihydrochloride is a potent inhibitor of the c-Src kinase (IC50 = 1.3 nM) and tyrosine kinases in the BTK and SYK family, as well as in the DDR2</p>Fórmula:C24H25Cl2N3O2SPureza:99.9%Cor e Forma:SoildPeso molecular:490.45Tinengotinib
CAS:<p>Tinengotinib is a multikinase inhibitor that targets a series of kinases , including Aurora kinases A/B, JAK1/2, FGFR1/2/3, VEGFRs, and many other kinases.</p>Fórmula:C20H19ClN6OPureza:99.05%Cor e Forma:SolidPeso molecular:394.86JBJ-07-149
CAS:<p>JBJ-07-149 is an inhibitor of EGFRL858R/T790M with an IC50 of 1.1 nM. It suppresses the proliferation of Ba/F3 cells with IC50 values of 4.9 μM when used alone, and 0.148 μM when combined with Cetuximab. Additionally, JBJ-07-149 can serve as a target protein ligand for synthesizing [DDC-01-163].</p>Fórmula:C28H26N6O2SCor e Forma:SolidPeso molecular:510.61Panomifene HCl
CAS:<p>Panomifene HCl is a selective anti-estrogenic compound with antitumor activity for the treatment of breast cancer.</p>Fórmula:C25H25ClF3NO2Pureza:99.53%Cor e Forma:SoildPeso molecular:463.92Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Cor e Forma:Odour SolidEGFR-IN-136
<p>EGFR-IN-136 (compound 21v) is a potent inhibitor of EGFR, demonstrating IC50 values of 20.2 nM, 1.2 nM, 2.3 nM, and 12.5 nM for EGFRWT, EGFRLR/TM, EGFR19D/TM/CS, and EGFRLR/TM/CS, respectively. It exhibits antiproliferative and antitumor activities and holds potential for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C30H36N7O4PCor e Forma:SolidPeso molecular:589.625EGFR T790M/L858R-IN-9
<p>EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.</p>Fórmula:C26H27N7O3SCor e Forma:SolidPeso molecular:517.603ARRY-380 (analog )
CAS:<p>ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.</p>Fórmula:C29H27N7O4SPureza:99.82%Cor e Forma:SolidPeso molecular:569.63EGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Fórmula:C17H16N4O4SCor e Forma:SolidPeso molecular:372.398BT-Amide
<p>BT-Amide is an orally active Pyk2 kinase (Pyk2kinase) inhibitor with an IC50 of 44.69 nM. It prevents glucocorticoid-induced bone loss and demonstrates bone-protective activity in C57BL/6 mice.</p>Fórmula:C29H38ClN7O11P2Cor e Forma:SolidPeso molecular:758.053[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)
CAS:<p>Insulin Receptor (1142-1153) binds insulin, is a substrate for its kinase, and has research/medical potential.</p>Fórmula:C72H110N19O33P3Pureza:98%Cor e Forma:SolidPeso molecular:1862.67ROS kinases-IN-2
CAS:<p>ROS kinases-IN-2 is a potent ROS kinase inhibitor with an inhibition rate of 21.53% measured at 10 μM.ROS kinases-IN-2 has potential anticancer activity and can</p>Fórmula:C22H19N3O3S2Pureza:99.65% - 99.66%Cor e Forma:SolidPeso molecular:437.54SU 4981
CAS:<p>SU 4981 is an inhibitor of VEGFR and a modulator of tyrosine kinase activity.</p>Fórmula:C19H18N2O2Pureza:95.4%Cor e Forma:SoildPeso molecular:306.36Herceptide
CAS:<p>Herceptide (HER2-targeting peptide), a peptide that targets HER2, can be conjugated with the near-infrared fluorescent dye indocyanine green (ICG), facilitating the development of theranostic agents.</p>Fórmula:C76H110N22O23Cor e Forma:SolidPeso molecular:1699.82Hck-IN-2
<p>Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.</p>Fórmula:C36H35FN6O10Cor e Forma:SolidPeso molecular:730.696Acrizanib
CAS:<p>Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2.</p>Fórmula:C20H18F3N7O2Pureza:98.71% - 99.64%Cor e Forma:SolidPeso molecular:445.4cFMS Receptor Inhibitor IV
CAS:<p>cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.</p>Fórmula:C22H26N4O2Pureza:99.70%Cor e Forma:SolidPeso molecular:378.47TL13-22
CAS:<p>TL13-22 is a potent inhibitor of ALK and does not lead to degradation of ALK proteins.TL13-22 is often used as a negative control for TL13-12 .</p>Fórmula:C45H55ClN10O9SPureza:99.13%Cor e Forma:SolidPeso molecular:947.5GNQWFI
CAS:<p>GNQWFI, an anti-Flt1 peptide, functions as a VEGFR1-specific antagonist. It inhibits interactions between VEGFR1 and various ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF), and suppresses VEGF-induced endothelial cell migration and tubulogenesis. GNQWFI holds potential for research in cancer, asthma, and other ocular diseases.</p>Fórmula:C37H49N9O9Cor e Forma:SolidPeso molecular:763.84Cinrebafusp alfa
CAS:<p>Cinrebafusp alfa (PRS 343) is an anticalin-based bispecific drug with high affinity for both CD137/HER2, displaying dissociation constants (Kd) of 0.3 nM to</p>Pureza:98%Cor e Forma:LiquidKemptide Phospho-Ser5
<p>Kemptide (Phospho-Ser5) is a phosphoreceptor peptide that is a specific substrate for camp-dependent protein kinase (PKA).</p>Fórmula:C32H62N13O12PPureza:98%Cor e Forma:SolidPeso molecular:851.89Proinsulin C-peptide (human)
CAS:<p>C-peptide, a 31-amino acid, links Proinsulin A & B chains for correct folding and function.</p>Fórmula:C129H211N35O48Pureza:98%Cor e Forma:SolidPeso molecular:3020.26EGFRvIII peptide (PEPvIII)
CAS:<p>PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.</p>Fórmula:C70H111N19O24SPureza:98%Cor e Forma:SolidPeso molecular:1634.81Cixutumumab
CAS:<p>Cixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding</p>Pureza:98.5% (SDS-PAGE); 97.5% (SEC-HPLC) - 98.5% (SDS-PAGE); 97.5% (SEC-HPLC)Cor e Forma:LiquidErbB-2-binding peptide
CAS:<p>ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].</p>Fórmula:C43H60N8O11Cor e Forma:SolidPeso molecular:864.98DDR Inhibitor 2
<p>DDR Inhibitor 2 (compound 5a) is a potent inhibitor of the discoidin domain receptor (DDR) with an IC50 value of 0.125 μM, and it is applicable in fibrotic disease research.</p>Fórmula:C21H23N7OCor e Forma:SolidPeso molecular:389.19641Modotuximab
CAS:<p>Modotuximab (DS 1024) is a humanized antibody targeting EGFR with antitumor activity that accelerates the internalization and degradation of EGFR.</p>Pureza:95.5% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.5% (SDS-PAGE); 99.3% (SEC-HPLC)Cor e Forma:LiquidGIP (3-42), human acetate
<p>GIP (3-42), human acetate is an antagonist of a glucose-dependent insulinotropic polypeptide (GIP) receptor and regulates insulin secretion and GIP metabolism</p>Pureza:98%Cor e Forma:LiquidWAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C22H19N3O3Pureza:98.05%Cor e Forma:SolidPeso molecular:373.4KRAS G12D inhibitor 25
CAS:<p>KRAS G12D inhibitor 25 (Compound 148) acts as an inhibitor for KRAS G12C and HSP90α, displaying IC50 values of <0.1 μM and 0.1-1 μM respectively. Additionally, it suppresses the proliferation of MIA PaCa-2 and NCI-H358 cell lines, with EC50 values of <0.1 μM and 0.1-1 μM correspondingly. This compound also promotes the degradation of ERBB2, exhibiting a DC50 of 0.1-1 μM.</p>Fórmula:C56H62ClN11O6Cor e Forma:SolidPeso molecular:1020.62NBI-31772
CAS:<p>NBI-31772 (NBI 31772) is the potent inhibitor of insulin-like growth factor-1 binding protein (IGFBP, Ki = 47 nM).</p>Fórmula:C17H11NO7Pureza:99.79%Cor e Forma:SolidPeso molecular:341.27MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Fórmula:C52H72N12O11Pureza:97.70%Cor e Forma:SolidPeso molecular:1041.2PROTAC EGFR degrader 10
CAS:<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>Fórmula:C49H65ClN10O7SCor e Forma:SolidPeso molecular:973.62[Pro3]-GIP (Mouse)
<p>GIP receptor blocker, 2.6μM IC50, hinders insulin release, regulates glucose in ob/ob mice, and enhances glucose tolerance.</p>Fórmula:C225H342N62O64SPureza:98%Cor e Forma:SolidPeso molecular:4971.62GW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Fórmula:C28H25ClFN5O3S2Pureza:98.68%Cor e Forma:SoildPeso molecular:598.11AVE1642
<p>AVE1642 is a human IgG monoclonal antibody (mAb) that specifically targets CD221/IGF1R. It has the ability to slow the growth of tumor xenografts and extend the survival of tumor-bearing nude mice. AVE1642 is applicable in the study of advanced solid tumors. Recommended isotype control: HumanIgG1kappa, Isotype Control.</p>Cor e Forma:Odour LiquidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSCor e Forma:SolidPeso molecular:490.98Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Fórmula:C25H27Cl2FN4O4Cor e Forma:SolidPeso molecular:537.41HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Cor e Forma:SolidPeso molecular:884.11DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Cor e Forma:LiquidSecretin, canine
CAS:<p>Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.</p>Fórmula:C131H222N44O41Pureza:98%Cor e Forma:SolidPeso molecular:3069.43EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SCor e Forma:SolidPeso molecular:916.06EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Fórmula:C27H37FN8O2Cor e Forma:SolidPeso molecular:524.633PKG inhibitor peptide
CAS:<p>PKG inhibitor; mimics H2B phosphorylation site; Ki=86mM; blocks synthetic substrates, not histone phosphorylation; stops PKA activity on histones.</p>Fórmula:C38H74N18O10Pureza:98%Cor e Forma:SolidPeso molecular:943.12cis-NVP-ADW742
CAS:<p>NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.</p>Fórmula:C28H31N5OCor e Forma:SolidPeso molecular:453.59H1-7 (histone H1 phosphorylation site), PKA Substrate
CAS:<p>H1-7 (histone H1 phosphorylation site), a synthetic polypeptide serving as a PKA substrate, demonstrates utility in PKA substrate applications [1] [2].</p>Fórmula:C31H58N14O9Cor e Forma:SolidPeso molecular:770.88Insulin α-chain (1-13)
CAS:<p>Insulin alpha-chain peptide, amino acids 1-13, T cell-recognized, posttranslationally modified.</p>Fórmula:C66H118N20O22S3Pureza:98%Cor e Forma:SolidPeso molecular:1639.96IGF-I (30-41)
CAS:<p>IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).</p>Fórmula:C51H83N19O19Pureza:98%Cor e Forma:SolidPeso molecular:1266.34GIP (1-30) amide,human
CAS:<p>GIP (1-30) amide (Human) is a glucose-dependent insulinotropic polypeptide that stimulates insulin secretion, reducing postprandial glycemic issues.</p>Fórmula:C162H240N40O47SPureza:98%Cor e Forma:SolidPeso molecular:3531.94DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Cor e Forma:Odour SolidSTAD 2
CAS:<p>STAD-2 is a cell permeable akap disruptor, selectively binding to pka-rii and blocking the interaction of pka-ri with akap</p>Fórmula:C102H182N24O22Cor e Forma:SolidPeso molecular:2096.724EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Fórmula:C22H16ClFN4O2Peso molecular:422.09458TrkA-IN-6
<p>TrkA-IN-6 (compound R48) is a hydrazone-based, selective inhibitor of the tropomyosin receptor kinase A (TrkA). It exhibits greater cytotoxicity towards U87 GBM cells compared to Temozolomide, with an IC50 of 68.99 μM.</p>Fórmula:C16H13N3O5Peso molecular:327.08552PKI(5-24)
CAS:<p>High affinity PKA inhibitor (Ki = 2.3 nM).</p>Fórmula:C76H129N31O28Pureza:98%Cor e Forma:SolidPeso molecular:1925.057pYEEI
<p>pYEEI, a tetrapeptide containing phosphotyrosine, binds to the SrcSH2 domain with a dissociation constant (Kd) of 100 nM and an inhibitory concentration (IC50) of 6.5 μM. This compound plays a crucial role in cancer research.</p>Fórmula:C25H36N3O14PCor e Forma:SolidPeso molecular:633.54PXB17
<p>PXB17 inhibits CSF1R activation (IC50= 1.7 nM) by blocking the PI3K/AKT/mTORC1 signaling pathway. It is effective orally, significantly suppresses the growth of colorectal cancer (CRC), enhances the efficacy of PD-1 monoclonal antibodies (PD-1mAb), and reduces the recurrence of CRC tumors.</p>Fórmula:C29H35N7O4Peso molecular:545.27505Dacomitinib metabolite M2
CAS:<p>Dacomitinib metabolite M2 is also known as Dacomitinib cysteine conjugate. Dacomitinib inhibits both the wild-type (WT) EGFR and EGFR T790M.</p>Fórmula:C27H32ClFN6O4SCor e Forma:SolidPeso molecular:591.1Sotuletinib hydrochloride
CAS:<p>Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM),for ALS and TNBC.</p>Fórmula:C20H23ClN4O3SPureza:98.812%Cor e Forma:SolidPeso molecular:434.94Vasonatrin Peptide (VNP)
CAS:<p>Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity</p>Fórmula:C123H198N36O36S3Pureza:98%Cor e Forma:SolidPeso molecular:2865.37MS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Fórmula:C50H59ClF4N8O14Cor e Forma:SolidPeso molecular:1107.5CZY43
<p>CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.</p>Fórmula:C42H53Cl2N5O3Cor e Forma:SolidPeso molecular:746.808IGF-I (24-41)
CAS:<p>IGF-I (24-41) is a fragment of IGF-I, affecting GH activities with anabolic, antioxidant, anti-inflammatory, and cytoprotective properties.</p>Fórmula:C88H133N27O28Pureza:98%Cor e Forma:SolidPeso molecular:2017.16PRMT5/EGFR-IN-1
<p>PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.</p>Fórmula:C27H22F6N2O2Peso molecular:520.15855EGFR/HER2-IN-15
<p>EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.</p>Fórmula:C28H29N3O6Peso molecular:503.20564GIP, human
CAS:<p>Insulinotropic hormone from K-cells, binds GIP receptors, boosts insulin, affects lipids, and has antiapoptotic properties.</p>Fórmula:C226H338N60O66SPureza:98%Cor e Forma:SolidPeso molecular:4983.6c-Kit-IN-6
<p>C-Kit-IN-6 (Compound 101) is an inhibitor of c-Kit, demonstrating IC50 values ranging from 100 nM to 1 μM.</p>Fórmula:C25H28FN5O5Cor e Forma:SolidPeso molecular:497.52Kemptide
CAS:<p>Kemptide is a synthetic heptapeptide, acting as a substrate for cAMP-dependent protein kinase (PK).</p>Fórmula:C32H61N13O9Pureza:98%Cor e Forma:SolidPeso molecular:771.91HER2-IN-20
<p>HER2-IN-20 (compound 32) is a potent and selective inhibitor of HER2WT and HER2YVMA, with IC50 values of 49 and 42 nM, respectively. It holds potential for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C30H27ClFN7O2Peso molecular:571.18988EGFR kinase inhibitor 2
<p>EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.</p>Fórmula:C39H40N6O5Peso molecular:672.30602ZM 449829
CAS:<p>ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.</p>Fórmula:C13H10OPureza:98%Cor e Forma:SolidPeso molecular:182.222EGFR-IN-93
<p>EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).</p>Fórmula:C22H18FN3O3Peso molecular:391.13322Enapotamab vedotin
CAS:<p>Enapotamab vedotin (anti-AXL ADC) targets AXL with MMAE payload, showing potential against AXL-expressing, EGFR-resistant NSCLC.</p>Pureza:95%Cor e Forma:LiquidTimigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Cor e Forma:LiquidHDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Fórmula:C17H11ClFN5OCor e Forma:SolidPeso molecular:355.76Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK.</p>Fórmula:C32H46N5O17PPureza:98%Cor e Forma:SolidPeso molecular:803.71HER2/neu (654-662) GP2 acetate
<p>GP2 acetate, from HER2 (654-662), triggers HLA-A2-restricted T cells to attack epithelial cancers.</p>Fórmula:C44H81N9O13Pureza:98%Cor e Forma:SolidPeso molecular:944.17Gastric Inhibitory Peptide (1-42) (porcine) TFA
<p>Gastric Inhibitory Peptide (1-42) (porcine) TFA is a glucose-dependent insulinotropic polypeptide released by intestinal K-cells.</p>Fórmula:C225H342N60O66S·XCF3COOHCor e Forma:SolidPeso molecular:4975.55EGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Fórmula:C23H28F2N8O3SPeso molecular:534.19731BI-4732
CAS:<p>DL-Homocystine is a mutagen secreted by F. nucleatum.</p>Fórmula:C32H36N10O2Pureza:98.88%Cor e Forma:SolidPeso molecular:592.69EGFR WT/T790M/L858R-IN-1
<p>EGFRWT/T790M/L858R-IN-1 (compound 10d) is a potent inhibitor of EGFR, demonstrating IC50 values of 0.097, 0.280, and 0.051 μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. This compound can be utilized in cancer research.</p>Fórmula:C26H25Cl3N2O3Peso molecular:518.09308evobrutinib
CAS:<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Fórmula:C25H27N5O2Pureza:98.03% - 99.58%Cor e Forma:SolidPeso molecular:429.51Anti-TrkB/NTRK2 Antibody
<p>Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.</p>Cor e Forma:Odour LiquidMS39N
CAS:<p>MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.</p>Fórmula:C55H71ClFN9O7SPeso molecular:1056.73CN009543V
CAS:<p>CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.</p>Fórmula:C12H12N4O6SCor e Forma:SolidPeso molecular:340.31IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Cor e Forma:Odour LiquidGNF2133
CAS:<p>GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.</p>Fórmula:C24H30N6O2Pureza:98.51%Cor e Forma:SolidPeso molecular:434.53Inetetamab
<p>Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.</p>Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Cor e Forma:Odour LiquidPROTAC EGFR degrader 3
CAS:<p>Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.</p>Fórmula:C60H77N13O5SCor e Forma:SolidPeso molecular:1092.4Insulin efsitora alfa
CAS:<p>Insulin efsitora alfa(LY-3209590) is an IR agonist and a fusion protein that binds a novel single-chain insulin variant to the structural domain of human IgG Fc</p>Pureza:98.3% (SDS-PAGE); 98.1% (SEC-HPLC) - 98.3% (SDS-PAGE); 98.1% (SEC-HPLC)Cor e Forma:LiquidEflapegrastim
CAS:<p>Eflapegrastim: humanized IgG4 antibody and G-CSF that boosts neutrophils and shortens neutropenia.</p>Cor e Forma:LiquidBTK-IN-40
CAS:<p>BTK-IN-40 (compound 375) is an inhibitor of BTK.</p>Fórmula:C20H25N7O2Cor e Forma:SolidPeso molecular:395.46YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Cor e Forma:Odour LiquidEtevritamab
CAS:<p>Etevritamab is a monoclonal antibody that targets CD3E/EGFR.</p>Cor e Forma:LiquidBTK inhibitor 17
CAS:<p>BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.</p>Fórmula:C25H24N6O3Pureza:99.57% - 99.88%Cor e Forma:SolidPeso molecular:456.5LDN-193189 2HCl
CAS:<p>LDN-193189 2HCl inhibits BMP signaling (ALK1/2/3/6), IC50: 0.8-16.7 nM; selective over TGF-β by 200-fold in C2C12 cells.</p>Fórmula:C25H24Cl2N6Pureza:99.78%Cor e Forma:SolidPeso molecular:479.4ODM-203 sodium
<p>ODM-203 sodium is an orally bioavailable selective and efficient FGFR and VEGFR inhibitor with antitumor activity, used in solid tumor research.</p>Fórmula:C26H20F2N5NaO2SPureza:99.89%Cor e Forma:SolidPeso molecular:527.52[D-Ala2]-GIP (human)
CAS:<p>Potent GIP receptor agonist with 630 pM EC50; enhances cAMP, glucose control, insulin, cognition in diabetic/obese animals; neuroprotective in PD model.</p>Fórmula:C226H338N60O66SPureza:98%Cor e Forma:SolidPeso molecular:4983.58Caffeic acid-pYEEIE
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).</p>Fórmula:C39H50N5O19PPureza:98%Cor e Forma:SolidPeso molecular:923.82Ack1 inhibitor 2
CAS:<p>Ack1 Inhibitor 2, also referred to as Example 259, effectively inhibits Ack1 with an IC50 value of 0.46 μM [1].</p>Fórmula:C23H23N5O2Cor e Forma:SolidPeso molecular:401.46AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Cor e Forma:Odour LiquidEP26
<p>EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.</p>Fórmula:C42H42ClFN4O5Peso molecular:736.28278MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47JAK 3 inhibitor IV
CAS:<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Fórmula:C16H19NOPureza:98%Cor e Forma:SolidPeso molecular:241.33SJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Fórmula:C57H61ClFN7O9SPureza:99.20%Cor e Forma:SolidPeso molecular:1074.65Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Fórmula:C29H49N4O10PPureza:98.01%Cor e Forma:SolidPeso molecular:644.69EGFR-IN-116
<p>EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.</p>Fórmula:C26H22N6O2SPeso molecular:482.1525PKA Inhibitor Fragment (6-22) amide TFA
<p>PKA Inhibitor Fragment (6-22) amide TFA (PKA Inhibitor Fragment (6-22) amide TFA) is an inhibitor of cAMP-dependent protein kinase A (PKA).</p>Fórmula:C82H131F3N28O26Pureza:99.61% - 99.87%Cor e Forma:SolidPeso molecular:1982.08SU 5616
CAS:<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Fórmula:C13H8ClNOSPureza:98.84%Cor e Forma:SoildPeso molecular:261.73EGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Cor e Forma:Odour SolidCalcineurin substrate
CAS:<p>Calcineurin Substrate is a Peptide from the regulatory RII subunit of cAMP-dependent protein kinase.</p>Fórmula:C92H150N28O29Pureza:98%Cor e Forma:SolidPeso molecular:2112.35Necitumumab
CAS:<p>Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.</p>Pureza:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.5 kDaEGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Cor e Forma:Odour SolidMotesanib Diphosphate
CAS:<p>Motesanib Diphosphate (AMG 706) is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic</p>Fórmula:C22H23N5O·2H3PO4Pureza:99.69%Cor e Forma:SolidPeso molecular:569.44Leucettine L41
CAS:<p>Leucettine L41 (LeucettineL41) is an inhibitor of DYRKs/CLKs, preferentially targeting DYRK1A, and inhibits DYRK2.</p>Fórmula:C17H13N3O3Pureza:99.08%Cor e Forma:SolidPeso molecular:307.3Mecbotamab vedotin
CAS:<p>Mecbotamab vedotin (BA301) is an inhibitory IgG1 antibody that targets human tyrosine kinase receptor AXL and the humanized murine monoclonal BA301 γ1 chain. It can be utilized in the preparation of immunoconjugates for research into cancers expressing the Axl type.</p>Cor e Forma:LiquidDSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidPROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SCor e Forma:SolidPeso molecular:1151.78Cetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Cor e Forma:LiquidPeso molecular:150 kDaKN1022
CAS:<p>KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.</p>Fórmula:C21H22N6O5Pureza:99.68%Cor e Forma:SoildPeso molecular:438.44Laprituximab
CAS:<p>Laprituximab (J2898A) is a humanized anti-EGFR antibody used for synthesizing ADC compound Laprituximab emtansine.</p>Pureza:>95%Cor e Forma:LiquidAntiproliferative agent-57
<p>Antiproliferative agent-57 (compound M2) is a tumor angiogenesis inhibitor that suppresses VEGF secretion in SiHa cells under hypoxic conditions without inducing cytotoxicity (IC50=0.68 μM). It modulates the PI3K/AKT/mTOR and MAPK signaling pathways in tumor cells, thereby inhibiting the expression of HIF-1α and VEGF within tumor tissues.</p>Cor e Forma:Odour SolidMS9449
CAS:<p>MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.</p>Fórmula:C60H76ClFN10O8SPureza:98%Cor e Forma:SolidPeso molecular:1151.82EGFR-IN-43
<p>EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.</p>Fórmula:C50H55ClFN5O5Cor e Forma:SolidPeso molecular:860.45EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Fórmula:C24H25BrN6O2Cor e Forma:SolidPeso molecular:509.408(Pro3) GIP, human
CAS:<p>(Pro3) GIP, human: stable hGIPR full agonist, high affinity (Ki/Kd=0.90nM), for obesity-related diabetes research.</p>Fórmula:C226H338N60O64SCor e Forma:SolidPeso molecular:4951.53Istiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Cor e Forma:LiquidPCI-33380
CAS:<p>PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.</p>Fórmula:C46H52BF2N11O3Pureza:98%Cor e Forma:SolidPeso molecular:855.8PD-149163 hydrochloride
<p>PD-149163 hydrochloride is a neurokinin B agonist with antipsychotic activity, used for research on neurological diseases.</p>Fórmula:C42H72ClN9O6Cor e Forma:SolidPeso molecular:834.53Arginyl-Glutamine
CAS:<p>Arginyl-Glutamine (Arg-Gln) is a dipeptide nutritional supplement that protects neonatal mice from hyperoxia-induced lung injury, lowering VEGF levels.</p>Fórmula:C11H22N6O4Pureza:95.2%Cor e Forma:SolidPeso molecular:302.33
![[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1259.webp&w=3840&q=75)
